Cargando…
Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives
Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963256/ https://www.ncbi.nlm.nih.gov/pubmed/27493880 http://dx.doi.org/10.1016/j.ymgmr.2016.07.003 |
_version_ | 1782444933991366656 |
---|---|
author | Shchelochkov, Oleg A. Dickinson, Klara Scharschmidt, Bruce F. Lee, Brendan Marino, Miguel Le Mons, Cynthia |
author_facet | Shchelochkov, Oleg A. Dickinson, Klara Scharschmidt, Bruce F. Lee, Brendan Marino, Miguel Le Mons, Cynthia |
author_sort | Shchelochkov, Oleg A. |
collection | PubMed |
description | Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patient, caregiver (CG) and physician perspectives on treatments used in urea cycle disorders (UCD). METHODS: A paper and online survey assessed experience with UCD medications, medical foods and dietary supplements. RESULTS: 25 physicians, 52 adult patients and 114 CG responded. In 2009, the most common UCD-specific intervention reported by patients included sodium phenylbutyrate (60%), followed by l-citrulline (46%), amino acid medical foods (15%), l-arginine preparations (18%), and sodium benzoate (8%). Only 36% of patients reported experiencing no hyperammonemic episodes in the last 2 years. The most commonly reported cause of hyperammonemic episodes was infection or other acute illnesses, followed by dietary indiscretion, side effects of medications, and drug non-adherence. Most patients, caregivers and physicians (> 75%) ranked nitrogen-scavenging medications, l-citrulline, l-arginine, and medical foods as “effective” or “very effective.” Non-adherence was common (e.g. 18% of patients admitted to missing sodium phenylbutyrate “at least once a week” and “at least one a day”). Barriers to adherence included taste of medications, frequency of drug administration, number of pills, difficulty swallowing pills, side effects, forgetting to take medications, and high cost. Strategies to mitigate the gastrointestinal side effects of medications included the use of gastric tubes and acid reflux medications. Physicians indicated that 25% and 33% of pediatric and adult patients, respectively, were given less than the recommended dose of sodium phenylbutyrate due to concerns of tolerance, administration, and cost. CONCLUSIONS: Despite positive views of their effectiveness, respondents found medications, medical foods and dietary supplements difficult to take and viewed adherence as inadequate, thus contributing to hyperammonemic episodes. |
format | Online Article Text |
id | pubmed-4963256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-49632562016-08-04 Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives Shchelochkov, Oleg A. Dickinson, Klara Scharschmidt, Bruce F. Lee, Brendan Marino, Miguel Le Mons, Cynthia Mol Genet Metab Rep Research Paper Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patient, caregiver (CG) and physician perspectives on treatments used in urea cycle disorders (UCD). METHODS: A paper and online survey assessed experience with UCD medications, medical foods and dietary supplements. RESULTS: 25 physicians, 52 adult patients and 114 CG responded. In 2009, the most common UCD-specific intervention reported by patients included sodium phenylbutyrate (60%), followed by l-citrulline (46%), amino acid medical foods (15%), l-arginine preparations (18%), and sodium benzoate (8%). Only 36% of patients reported experiencing no hyperammonemic episodes in the last 2 years. The most commonly reported cause of hyperammonemic episodes was infection or other acute illnesses, followed by dietary indiscretion, side effects of medications, and drug non-adherence. Most patients, caregivers and physicians (> 75%) ranked nitrogen-scavenging medications, l-citrulline, l-arginine, and medical foods as “effective” or “very effective.” Non-adherence was common (e.g. 18% of patients admitted to missing sodium phenylbutyrate “at least once a week” and “at least one a day”). Barriers to adherence included taste of medications, frequency of drug administration, number of pills, difficulty swallowing pills, side effects, forgetting to take medications, and high cost. Strategies to mitigate the gastrointestinal side effects of medications included the use of gastric tubes and acid reflux medications. Physicians indicated that 25% and 33% of pediatric and adult patients, respectively, were given less than the recommended dose of sodium phenylbutyrate due to concerns of tolerance, administration, and cost. CONCLUSIONS: Despite positive views of their effectiveness, respondents found medications, medical foods and dietary supplements difficult to take and viewed adherence as inadequate, thus contributing to hyperammonemic episodes. Elsevier 2016-07-20 /pmc/articles/PMC4963256/ /pubmed/27493880 http://dx.doi.org/10.1016/j.ymgmr.2016.07.003 Text en © 2016 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Shchelochkov, Oleg A. Dickinson, Klara Scharschmidt, Bruce F. Lee, Brendan Marino, Miguel Le Mons, Cynthia Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title | Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title_full | Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title_fullStr | Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title_full_unstemmed | Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title_short | Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives |
title_sort | barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963256/ https://www.ncbi.nlm.nih.gov/pubmed/27493880 http://dx.doi.org/10.1016/j.ymgmr.2016.07.003 |
work_keys_str_mv | AT shchelochkovolega barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives AT dickinsonklara barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives AT scharschmidtbrucef barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives AT leebrendan barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives AT marinomiguel barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives AT lemonscynthia barrierstodrugadherenceinthetreatmentofureacycledisordersassessmentofpatientcaregiverandproviderperspectives |